Despite encouraging Phase I/II data for its allogeneic DC approach in metastatic RCC and a larger Phase II trial now underway, investors are cautious of novel DC transfer therapies. Data expected over the next 12-18 months, if positive, would allow the company to seek a partner.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Advancing dendritic cell therapeutics
Despite encouraging Phase I/II data for its allogeneic DC approach in metastatic RCC and a larger Phase II trial now underway, investors are cautious of novel DC transfer therapies. Data expected over the next 12-18 months, if positive, would allow the company to seek a partner.